EWM
CRVS icon

Empirical Wealth Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Empirical Wealth Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-167,400
Closed -$1.29M – 1007
2025
Q4 		$1.29M Sell
167,400
-1,800
-1% -$14.2K 0.02% 300
2025
Q3 		$1.25M Buy
169,200
+1,200
+0.7% +$6.14K 0.02% 304
2025
Q2 		$672K Buy
+168,000
New +$611K 0.02% 374

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Empirical Wealth Management's CRVS Position: Q1 2026 in Review

Empirical Wealth Management sold out of Corvus Pharmaceuticals (CRVS) in Q1 2026, closing a stake of 167,400 shares — an estimated $1.29M sold.

Empirical Wealth Management first reported a position in CRVS in Q2 2025 and held it in 3 quarters. The position peaked at $1.29M in Q4 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Empirical Wealth Management reported no remaining Corvus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Empirical Wealth Management sold 167,400 Corvus Pharmaceuticals shares in Q1 2026, an estimated $1.29M.
  • Empirical Wealth Management first reported a position in Corvus Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Empirical Wealth Management's Corvus Pharmaceuticals position peaked at $1.29M in Q4 2025.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Empirical Wealth Management's 13F filing for Q1 2026, filed 4 May 2026.